Current status and perspectives of patient-derived rare cancer models

Human Cell
Tadashi Kondo

Abstract

Malignancies with extremely low incidences, such as less than 6 per 100,000 people annually, are defined as rare cancers. Approximately 200 malignancies are classified in this category, therefore the total number of patients with rare cancers is greater than that of patients with any single common cancer. However, because of the small numbers of patients, novel therapies have not been developed for individual rare cancers, and clinical outcomes remain dismal. Patient-derived cancer models are indispensable for both basic and pre-clinical studies, and their roles will increase in the era of post-genome medicine. Although patient-derived cancer models have long been used in oncology, they are not well developed for rare cancers. In the context of sarcoma, the presently available cell lines and xenograft models are limited and do not satisfy the needs of research. Indeed, the lack of effective therapies for rare cancers might be attributable to the paucity of adequate patient-derived cancer models for pre-clinical studies. To facilitate the establishment and availability of patient-derived rare cancer models, we need to create effective methods for model establishment, share the valuable clinical samples and established models, an...Continue Reading

References

Jan 1, 1985·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·H H FiebigH Arnold
Nov 1, 1973·Journal of the National Cancer Institute·D J GiardW P Parks
Jan 1, 1995·Cancer·R W MillerB Novakovic
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela J GoodwinNicky Hood
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Sep 3, 2003·Nature Reviews. Cancer·Lee J Helman, Paul Meltzer
Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Feb 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I Ray-CoquardJ-Y Blay
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tetsuya MitsudomiYasushi Yatabe
Jun 9, 2005·Biochemical and Biophysical Research Communications·Heinz-Juergen Hausser, Rolf E Brenner
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohammad I ZiaEric X Chen
Jul 25, 2006·Nature Reviews. Cancer·Levi A Garraway, William R Sellers
Feb 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John K ChanDaniel S Kapp
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaap Verweij
Mar 20, 2010·Nature Reviews. Cancer·Sreenath V SharmaJeff Settleman
Apr 16, 2010·Nature·UNKNOWN International Cancer Genome ConsortiumHuanming Yang
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Sep 9, 2010·Advances in Experimental Medicine and Biology·Gemma GattaUNKNOWN RARECARE Working Group
Sep 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael L MaitlandMark J Ratain
Mar 30, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jumpei KondoMasahiro Inoue
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jul 15, 2011·Nature Reviews. Cancer·Barry S TaylorMarc Ladanyi
Oct 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Gemma GattaUNKNOWN RARECARE working group
Nov 10, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jean-Pierre GilletMichael M Gottesman
Apr 18, 2012·Nature Reviews. Clinical Oncology·John J TentlerS Gail Eckhardt
Jul 20, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Dec 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Muling MaoScott Kopetz
Jan 3, 2013·International Journal of Cancer. Journal International Du Cancer·Neill PataniMitch Dowsett
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tianhong LiDavid R Gandara
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
Jun 25, 2013·Nature·UNKNOWN Cancer Genome Atlas Research Network
Jul 11, 2013·Nature Communications·Silvia DomckeNikolaus Schultz
Jan 11, 2014·Nature Biotechnology·Michael HayJesse Rosenthal
Apr 8, 2014·Cancer·Justin StebbingDavid Sidransky
Jul 6, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Apostolia-Maria TsimberidouDonald Berry
Aug 27, 2014·Cancer Epidemiology·Tomoko TamakiAkiko Shibata

❮ Previous
Next ❯

Citations

Jul 29, 2020·Japanese Journal of Clinical Oncology·Akira KawaiToshirou Nishida

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
biopsy
xenograft

Software Mentioned

RARECARE
RARECARENet
PDX Finder

Related Concepts

Related Feeds

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.